| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
84,571,000 |
| Market
Cap: |
160.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7304 - $3.24 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s first two products were approved by the U.S. Food and Drug Administration, European Medicines Agency, and Swiss Agency for Therapeutic Products. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
59,611 |
74,217 |
| Total Buy Value |
$0 |
$0 |
$86,148 |
$171,738 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
0 |
0 |
1,913 |
51,775 |
| Total Sell Value |
$0 |
$0 |
$2,686 |
$239,770 |
| Total People Sold |
0 |
0 |
1 |
4 |
| Total Sell Transactions |
0 |
0 |
5 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Warren Eric |
Chief Commercial Officer |
• – – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
54,106 |
|
- |
|
| Koenig Sheldon L. |
President and CEO |
• • – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
116,000 |
195,288 |
|
- |
|
| Foody Joanne M. |
Chief Medical Officer |
• – – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
112,978 |
|
- |
|
| Warren Eric |
Chief Commercial OfficerOffice |
• – – |
2022-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,106 |
|
46% |
|
| Looker Benjamin |
General Counsel |
• – – |
2022-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
70,800 |
70,800 |
|
- |
|
| Foody Joanne M. |
Chief Medical Officer |
• – – |
2021-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
62,528 |
62,528 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
31,768 |
|
- |
|
| Berkowitz Jeffrey |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
23,449 |
|
- |
|
| Woody Tracy M |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
28,416 |
|
- |
|
| Mcgovern Mark E |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
28,449 |
|
- |
|
| Fuhrman Alan |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
25,254 |
|
- |
|
| Janney Daniel |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
23,449 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
23,449 |
|
- |
|
| Gotto Antonio M Jr MD D Phil |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,376 |
23,449 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-05-24 |
4 |
B |
$20.22 |
$2,021,620 |
D/D |
100,000 |
4,477,964 |
2.45 |
-39% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-05-19 |
4 |
B |
$20.37 |
$4,073,960 |
D/D |
200,000 |
4,377,964 |
2.45 |
-38% |
|
| Koenig Sheldon L. |
President and CEO |
• • – |
2021-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
50,000 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-05-06 |
4 |
B |
$20.57 |
$1,645,632 |
D/D |
80,000 |
4,177,964 |
2.45 |
-45% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-05-05 |
4 |
B |
$20.02 |
$3,002,850 |
D/D |
150,000 |
4,097,964 |
2.45 |
-42% |
|
| Bartram Richard |
Chief Financial Officer |
• – – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
23,617 |
|
- |
|
| Hall Ashley |
Chief Development Officer |
• – – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
22,500 |
|
- |
|
| Koenig Sheldon L. |
Chief Operating Officer |
• – – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2020-12-30 |
4 |
OE |
$2.10 |
$22,427 |
D/D |
10,700 |
122,698 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2020-11-03 |
4 |
B |
$25.31 |
$5,062,120 |
D/D |
200,000 |
3,947,964 |
2.45 |
21% |
|
| Janney Daniel |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
11,073 |
|
- |
|
250 Records found
|
|
Page 3 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (4.52%) 
